Bevacizumab Versus Ranibizumab for Refractory Diabetic Macular Edema

University of Sao Paulo1 site in 1 country53 target enrollmentApril 2010

ConditionsDiabetic Retinopathy Macular Edema

InterventionsBevacizumab Ranibizumab

DrugsBevacizumab Ranibizumab

Overview

Phase: Phase 2
Intervention: Bevacizumab
Conditions: Diabetic Retinopathy
Sponsor: University of Sao Paulo
Enrollment: 53
Locations: 1
Primary Endpoint: Central subfield macular thickness (CSFT) change
Last Updated: 14 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to compare the morphological and visual acuity outcomes associated with 1.5 mg bevacizumab versus 0.5 ranibizumab intravitreal injections for treatment of diabetic macular edema.

Registry

clinicaltrials.gov

Start Date

April 2010

End Date

September 2012

Last Updated

14 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

University of Sao Paulo

Responsible Party

Principal Investigator

Rodrigo Jorge

Principal investigator

University of Sao Paulo

Eligibility Criteria

Inclusion Criteria

•Center-involving Diabetic macular edema unresponsive to LASER therapy performed at least 3 moths prior to inclusion;
•Best corrected visual acuity equal or worse than 20/40 and better than 20/800;
•Central subfield macular thickness greater than 300 µm